Italy’s Sunshine Act Is Coming: Is Your Organisation Ready for Transparency Reporting?

Understanding the Italian Sunshine Reporting obligations — and why early preparation makes all the difference.

Italy is on the cusp of a landmark shift in pharmaceutical and medical device transparency. The Italian Sunshine Act is moving closer to operational implementation and the Ministry of Health has confirmed that its continued implementation and the launch of ‘Sanità Trasparente’ remain part of its 2026 agenda. While the exact go-live date depends on the final implementation steps and formal activation of the register, organisations should not treat this as a distant issue.

For life science companies which have already been tracking relationships with subjects operating in the health sector and healthcare organisations across multiple departments, the question is no longer whether to prepare, but how well-prepared you already are.

For those still assessing their readiness, the clock is ticking.

What the Italian Sunshine Act Requires

The Italian Sunshine Reporting framework is structured around two key articles. Article 3 covers the disclosure of transfers of value — which include consultancy agreements, fee-for-service arrangements, grants, clinical research payments, hospitality, travel, accommodation, entertainment, and gifts provided to HCPs and HCOs. Article 4 goes further, requiring disclosure of ownership and investment interests held by HCPs in life sciences companies.

Under the proposed timeline, companies must begin tracking Article 3 TOVs from the moment the Ministry of Health implementation decree is signed, potentially as early as the second half of 2026, with the first submission to the Ministry due by June 30, 2027. Article 4 disclosures follow a year later, with the first report due January 2028.

This is not a single-department exercise. Organisations that begin mapping their obligations now will discover that TOVs touch nearly every corner of the business, from marketing and R&D to HR, clinical affairs, sales, and even corporate finance.

The Departments Most Likely to Have Reporting Obligations

One of the most common surprises for companies undertaking their first TOV assessment is the sheer breadth of departments involved. The most obvious areas, marketing and scientific affairs, hold agreements with key opinion leaders, congress sponsorships, and travel and hospitality arrangements that clearly fall within scope. However, Italian companies also need to consider less obvious interactions.

For example, Italian labour law requires employers to appoint a competent company physician (medico competente) to carry out workplace health checks on employees. The fee paid to this physician — who is an HCP — may itself constitute a reportable TOV. Similarly, departments managing royalty agreements, clinical trial partnerships, or free-of-charge instrument placements with healthcare organisations all need to be examined.

HR teams organising training events where HCPs are engaged as speakers, product development teams managing travel and accommodation for clinical input, and even foundations awarding STEM engagement fees to scientific professionals, all of these interactions potentially fall within scope. A thorough internal assessment, department by department, is essential to ensure nothing is missed.

Building a Scalable, Defensible Internal Process

The companies best positioned for Italian Sunshine compliance are those that have embedded accountability at the departmental level. Rather than relying on a single compliance officer to gather data from across the organisation, a mature process distributes ownership: each department that interacts with HCPs is responsible for identifying, recording, and submitting its own TOV data, accompanied by an attestation confirming completeness and accuracy.

This approach has several advantages. It makes data collection scalable, reduces the bottleneck on any single individual, creates a clear audit trail, and crucially distributes liability appropriately. When every department head formally attests to their data, the risk of an individual oversight undermining the entire submission is significantly reduced.

The use of standardised Excel templates, shared in advance with all relevant teams, ensures consistency in how data is captured across the organisation. A central consolidator then reviews the incoming data for completeness and consistency before it is submitted for processing and XML generation.

Start Now — Even If the Decree Is Not Yet Signed

A common misconception is that there is no need to act until the Ministry of Health formally signs the implementation decree. In reality, the setup and testing phase, defining your data collection methodology, configuring IT access, running test data collections, and familiarising your team with the submission portal, can and should be done in advance. When the decree is signed, companies that have already completed these steps will be able to focus on data quality rather than scrambling to build processes from scratch.

The Italian Ministry of Health has confirmed in its official Goal of the Year document that implementation of the Sunshine Act is a 2026 priority (Chapter 7.9). The direction of travel is clear.

Whether your organisation is at the very beginning of its compliance journey or already consolidating data from internal departments, expert support can significantly reduce the burden on your team, and meaningfully improve the quality and defensibility of your submission.

Ready to understand exactly where your organisation stands on Italian Sunshine Reporting? Get in touch today with our experts to get tailored guidance and take the first step towards a confident, audit-ready submission.